RNXT

RenovoRx, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Voll MarkChief Financial Officer
$20k25k shares
BuyMay 19, 2026
$0.7876
--
Bagai ShaunDirector, Officer: Chief Executive Officer
Disclosure amount unavailable24.3k shares
BuyMar 20, 2026
--
--
Marton LaurenceDirector
Disclosure amount unavailable9.7k shares
BuyMar 20, 2026
--
--
Voll MarkChief Financial Officer
Disclosure amount unavailable97.2k shares
BuyMar 20, 2026
--
--
Voll MarkChief Financial Officer
$94k48.6k shares
BuyMar 20, 2026
$1.93
--
Bagai ShaunDirector, Officer: Chief Executive Officer
$23k12.2k shares
BuyMar 20, 2026
$1.93
--

News

globenewswire.comRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancerglobenewswire.comJun 11globenewswire.comRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rdglobenewswire.comJun 4globenewswire.comRenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancerglobenewswire.comMay 28globenewswire.comRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meetingglobenewswire.comMay 26globenewswire.comRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20thglobenewswire.comMay 19